Swedish Orphan Biovitrum

This study tested the safety and effectiveness of emapalumab in 13 Chinese patients with primary hemophagocytic lymphohistiocytosis (pHLH), a rare and severe immune disorder. All patients had already received some treatment. The goal was to see if emapalumab could control the dis…

This study tested a new medicine called SEL-212 in 153 adults with chronic gout that did not get better with standard treatments. The goal was to see if SEL-212 could safely lower uric acid levels below a target threshold for at least 80% of the time over six months. Participants…

This study tested an experimental drug called SEL-212 in 112 adults with chronic gout that standard treatments couldn't control. Participants received one of two doses of SEL-212 or a placebo every 28 days for about 6 months. The main goal was to see if SEL-212 could lower and ke…

This study tested a drug called emapalumab in 33 children and adults with a dangerous immune overreaction (macrophage activation syndrome) caused by Still's disease or lupus. The goal was to see if the drug could calm the immune system and improve blood test results when standard…

This study tested a drug called pegcetacoplan in 12 adults who developed a serious blood clotting condition (TA-TMA) after a stem cell transplant. The goal was to see how the drug moves through the body, if it helps control the disease, and if it is safe. While not a cure, the ap…

This study tested a drug called pegcetacoplan in 24 adults with cold agglutinin disease, a rare condition where the immune system destroys red blood cells, causing anemia. The goal was to see if the drug could safely increase hemoglobin levels and reduce the need for blood transf…

This study followed 151 people with hemophilia B for 24 months to see how well Alprolix works in everyday use. Researchers tracked bleeding episodes, how often the medicine was given, and how much was used. The goal was to understand real-world effectiveness, not to test a new tr…

This study looked back at the medical records of 32 people with Still's disease who also developed a serious complication called macrophage activation syndrome (MAS). The goal was to learn more about their symptoms, how they were treated, and how they recovered. By analyzing past…